home / stock / slncf / slncf quote
Last: | $8 |
---|---|
Change Percent: | 0.0% |
Open: | $8 |
Close: | $8 |
High: | $8 |
Low: | $8 |
Volume: | 625 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8 | $8 | $8 | $8 | $8 | 625 | 04-18-2024 |
$8 | $8 | $8 | $8 | $8 | 1,250 | 04-15-2024 |
$7.9 | $7.9 | $7.9 | $7.9 | $7.9 | 216 | 04-11-2024 |
$7 | $8.74 | $7 | $8.74 | $7 | 798 | 04-09-2024 |
$6.5 | $6.5 | $6.5 | $6.5 | $6.5 | 1,100 | 04-04-2024 |
$7.75 | $7.5 | $7.75 | $7.75 | $7.5 | 1,600 | 04-01-2024 |
$7.5 | $7.5 | $7.5 | $7.587 | $7.5 | 1,810 | 03-29-2024 |
$7.5 | $7.5 | $7.5 | $7.587 | $7.5 | 1,810 | 03-28-2024 |
$9 | $9.5 | $9 | $9.5 | $9 | 755 | 03-22-2024 |
$9 | $10 | $9 | $10.9 | $9 | 1,350 | 03-20-2024 |
$9 | $8.25 | $9 | $9 | $8.25 | 2,670 | 03-19-2024 |
$8.5 | $9.85 | $8.5 | $10.84 | $8.5 | 2,170 | 03-18-2024 |
$8 | $8 | $8 | $8 | $8 | 400 | 03-15-2024 |
$7.4 | $7.4 | $7.4 | $7.4 | $5.55 | 4,587 | 03-06-2024 |
$7.45 | $0 | $7.45 | $0 | $0 | 1 | 03-04-2024 |
$7.45 | $7.49 | $7.45 | $7.49 | $7.45 | 1,790 | 03-01-2024 |
$5.7 | $3.58 | $5.7 | $5.7 | $3.58 | 2,765 | 02-29-2024 |
$3.55 | $3.55 | $3.55 | $3.55 | $3.55 | 1,000 | 02-23-2024 |
$3.55 | $3.55 | $3.55 | $3.55 | $3.55 | 500 | 02-22-2024 |
$3.25 | $3.25 | $3.25 | $3.25 | $3.25 | 500 | 02-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Ord Company Name:
SLNCF Stock Symbol:
OTCMKTS Market:
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will partic...
Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, wh...
Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosing Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to ...